Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2010-11-07
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 10
- Registration Number
- NCT00010439
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Bone Loss in Premenopausal Women With Depression
- Conditions
- First Posted Date
- 2000-08-18
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 220
- Registration Number
- NCT00006180
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
- First Posted Date
- 2000-03-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Dennis Black
- Target Recruit Count
- 238
- Registration Number
- NCT00005005
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Maine Center for Osteoporosis, Bangor, Maine, United States
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2000-03-27
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Helen Hayes Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT00005006
- Locations
- 🇺🇸
Helen Hayes Hospital, Clinical Research Center, West Haverstraw, New York, United States
Effects of Parathyroid Hormone in Men With Osteoporosis
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00000427
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2007-01-04
- Target Recruit Count
- 240
- Registration Number
- NCT00000430
- Locations
- 🇺🇸
Creighton University Osteoporosis Research Center, Omaha, Nebraska, United States
Alendronate and/or Parathyroid Hormone for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT00000400
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Osteoporosis Prevention After Heart Transplant
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 149
- Registration Number
- NCT00000412
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Columbai University Medical Center, New York, New York, United States
Treatment of Childhood Osteoporosis With Alendronate (Fosamax)
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2016-09-22
- Target Recruit Count
- 50
- Registration Number
- NCT00001720
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.